Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)

Dianthus Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $19.5 million for Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 48.78% year-over-year to $19.5 million in Q4 2025; TTM through Dec 2025 was $19.5 million, a 48.78% increase from a year earlier, with the FY2025 full-year figure at $19.5 million, up 48.78% from the prior year.
• Accumulated Expenses improved to $19.5 million in Q4 2025 per DNTH's latest filing, from $16.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $19.5 million in Q4 2025 and bottomed at $1.6 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $7.4 million (2021), against an average of $8.4 million.
• Across the five-year window, Accumulated Expenses slumped 75.55% in 2023 and jumped 273.13% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $7.8 million in 2021, then retreated by 15.53% to $6.6 million in 2022, then slipped by 1.57% to $6.5 million in 2023, then soared by 101.01% to $13.1 million in 2024, then surged by 48.78% to $19.5 million in 2025.
• Per Business Quant, the three latest DNTH Accumulated Expenses figures stand at $19.5 million (Q4 2025), $16.0 million (Q3 2025), and $14.0 million (Q2 2025).